Nanomedicine as a potential novel therapeutic approach against the dengue virus

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Goncalvez AP, Engle RE, Claire MS, Purcell RH, Lai C-J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl Acad. Sci. USA 104(22), 9422–9427 (2007).
  Medline CASGoogle Scholar
• 2. Zohra T, Khalil AT, Saeed F et al. Green nano-biotechnology: a new sustainable paradigm to control dengue infection. Bioinorg. Chem. Appl. 2022, 3994340 (2022). • Highlights the use of green nanotechnology for the management of dengue infection. The use of photosynthesized nanoparticles is reported to be effective against the vector and to be devoid of hazardous effects.
  MedlineGoogle Scholar
• 3. Villabona-Arenas CJ, de Oliveira JL, de Sousa Capra C et al. Detection of four dengue serotypes suggests rise in hyperendemicity in urban centers of Brazil. PLOS Negl. Trop. Dis. 8(2), e2620 (2014). • Reports the presence of four dengue serotypes in a single outbreak, responsible for hyperendemicity in Brazilian urban areas.
  MedlineGoogle Scholar
• 4. Chen Q, Li R, Wu B, Zhang X, Zhang H, Chen R. A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement. Front. Immunol. 14, 1193175 (2023). •• Modified envelope proteins from four DENV serotypes were formulated in a 24-mer ferritin nanoparticle. The tetravalent vaccine effectively induced cellular and humoral immunity in rodents without antibody-dependent enhancement of infection and offered considerable protection against the DENV-2 and DENV-3 lethal challenge.
  Medline CASGoogle Scholar
• 5. Brady OJ, Hay SI. The global expansion of dengue: how Aedes aegypti mosquitoes enabled the first pandemic arbovirus. Ann. Rev. Entomol. 65, 191–208 (2020).
  Medline CASGoogle Scholar
• 6. Murugan K, Wei J, Alsalhi MS et al. Magnetic nanoparticles are highly toxic to chloroquine-resistant Plasmodium falciparum, dengue virus (DEN-2), and their mosquito vectors. Parasitol. Res. 116(2), 495–502 (2017). • Study of the efficacy of magnetic nanoparticles against chloroquine-sensitive and -resistant strains of Plasmodium falciparum, DEN-2 and other vectors. Nanoparticles exhibited toxicity against larvae and pupae with considerable potency, but in vivo efficacy was comparatively low.
  MedlineGoogle Scholar
• 7. Wellekens K, Betrains A, De Munter P, Peetermans W. Dengue: current state one year before WHO 2010-2020 goals. Acta Clin. Belg. 77(2), 436–444 (2022).
  Medline CASGoogle Scholar
• 8. Hadinegoro S. The revised WHO dengue case classification: does the system need to be modified? Paediatr. Int. Child Health 32(Suppl. 1), 33–38 (2012).
  MedlineGoogle Scholar
• 9. Ajlan BA, Alafif MM, Alawi MM, Akbar NA, Aldigs EK, Madani TA. Assessment of the new World Health Organization’s dengue classification for predicting severity of illness and level of healthcare required. PLOS Negl. Trop. Dis. 13(8), e0007144 (2019).
  MedlineGoogle Scholar
• 10. Swaminathan S, Khanna N. Experimental dengue vaccines. Int. J. Infect. Dis. 135–151, https://doi.org/10.1007/978-3-7091-1419-3_7 (2013).
  Google Scholar
• 11. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. World Health Organization, Geneva, Switzerland (2009).
  Google Scholar
• 12. Balmaseda A, Hammond SN, Pérez MA et al. Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am. J. Trop. Med. Hyg. 73(6), 1059–1062 (2005).
  MedlineGoogle Scholar
• 13. Alexander N, Balmaseda A, Coelho IC et al. Multicentre prospective study on dengue classification in four south-east Asian and three Latin American countries. Trop. Med. Int. Health 16(8), 936–948 (2011).
  MedlineGoogle Scholar
• 14. Pitisuttithum P, Bouckenooghe A. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Rev. Vaccines 15(7), 795–798 (2016). • Reports the clinical approval of the first dengue vaccine: a recombinant live, attenuated, tetravalent dengue vaccine formulated by Sanofi Pasteur.
  Medline CASGoogle Scholar
• 15. Fusco D, Chung RT. Review of current dengue treatment and therapeutics in development. J. Bioanal. Biomed. 8, doi:10.4172/1948-593x.s8-002 (2014).
  Google Scholar
• 16. Malik S, Ahsan O, Mumtaz H, Tahir Khan M, Sah R, Waheed Y. Tracing down the updates on dengue virus – molecular biology, antivirals, and vaccine strategies. Vaccines 11(8), 1328 (2023).
  CASGoogle Scholar
• 17. Speight G, Coia G, Parker M, Westaway EG. Gene mapping and positive identification of the non-structural proteins NS2A, NS2B, NS3, NS4B and NS5 of the flavivirus Kunjin and their cleavage sites. J. Gen. Virol. 69(1), 23–34 (1988).
  Medline CASGoogle Scholar
• 18. Jain SK. Molecular mechanism of pathogenesis of dengue virus: entry and fusion with target cell. Indian J. Clin. Biochem. 20(2), 92–103 (2005).
  MedlineGoogle Scholar
• 19. Bizzarro B, Barros MS, Maciel C et al. Effects of Aedes aegypti salivary components on dendritic cell and lymphocyte biology. Parasit. Vectors 6(1), 329 (2013).
  MedlineGoogle Scholar
• 20. Bielefeldt-Ohmann H, Meyer M, Fitzpatrick DR, Mackenzie JS. Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. Virus Res. 73(1), 81–89 (2001).
  Medline CASGoogle Scholar
• 21. Tuiskunen Bäck A, Lundkvist Å. Dengue viruses – an overview. Infect. Ecol. Epidemiol. 3(1), 19839 (2013).
  Google Scholar
• 22. Srikiatkhachorn A, Mathew A, Rothman AL. Immune-mediated cytokine storm and its role in severe dengue. Semin. Immunopathol. 39(5), 563–574 (2017).
  Medline CASGoogle Scholar
• 23. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J. Virol. 81(4), 1592–1600 (2007).
  Medline CASGoogle Scholar
• 24. Gonçalves D, de Queiroz Prado R, Almeida Xavier E et al. Imunocompetent mice model for dengue virus infection. Sci. World J. 2012, 525947 (2012).
  Google Scholar
• 25. Zheng W, Yan Q, Li Z et al. Liver transcriptomics reveals features of the host response in a mouse model of dengue virus infection. Front. Immunol. 13, 892469 (2022).
  Medline CASGoogle Scholar
• 26. Byrne AB, García AG, Brahamian JM et al. A murine model of dengue virus infection in suckling C57BL/6 and BALB/c mice. Animal Model Exp. Med. 4(1), 16–26 (2021).
  Medline CASGoogle Scholar
• 27. Spiropoulou CF, Srikiatkhachorn A. The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome. Virulence 4, 525–536 (2013).
  MedlineGoogle Scholar
• 28. Zompi S, Harris E. Animal models of dengue virus infection. Viruses 4, 62–82 (2012).
  Medline CASGoogle Scholar
• 29. Orozco S, Schmid MA, Parameswaran P et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J. Gen. Virol. 93(Pt 10), 2152 (2012).
  Medline CASGoogle Scholar
• 30. Rasmussen SB, Reinert LS, Paludan SR. Innate recognition of intracellular pathogens: detection and activation of the first line of defense. APMIS 117(5–6), 323–337 (2009).
  Medline CASGoogle Scholar
• 31. Navarro-Sánchez E, Desprès P, Cedillo-Barrón L. Innate immune responses to dengue virus. Arch. Med. Res. 36(5), 425–435 (2005).
  Medline CASGoogle Scholar
• 32. Diamond MS, Harris E. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 289(2), 297–311 (2001).
  Medline CASGoogle Scholar
• 33. Aguirre S, Maestre AM, Pagni S et al. DENV inhibits type I IFN production in infected cells by cleaving human Sting. PLOS Pathol. 8(10), e1002934 (2012).
  MedlineGoogle Scholar
• 34. Miesen P, Ivens A, Buck AH, Van Rij RP. Small RNA profiling in dengue virus 2-infected Aedes mosquito cells reveals viral piRNAs and novel host miRNAs. PLOS Negl. Trop. Dis. 10(2), e0004452 (2016).
  MedlineGoogle Scholar
• 35. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364(2), 272–280 (2008).
  Medline CASGoogle Scholar
• 36. Swaminathan G, Thoryk EA, Cox KS et al. A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates. Sci. Rep. 6(1), 34215 (2016).
  Medline CASGoogle Scholar
• 37. Nikaeen G, Abbaszadeh S, Yousefinejad S. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses. Nanomedicine 15(15), 1501–1512 (2020).
  CASGoogle Scholar
• 38. Sarker A, Dhama N, Gupta RD. Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement. Front. Immunol. 14, 1200195 (2023).
  Medline CASGoogle Scholar
• 39. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Ann. Rev. Biomed. Eng. 14, 1–16 (2012).
  Medline CASGoogle Scholar
• 40. Aguiar M, Stollenwerk N, Halstead SB. The impact of the newly licensed dengue vaccine in endemic countries. PLOS Negl. Trop. Dis. 10(12), e0005179 (2016). • Epidemiological study that reported the considerable protective efficacy of the CYD-TDV vaccine against dengue infections.
  MedlineGoogle Scholar
• 41. Khetarpal N, Khanna I. Dengue fever: causes, complications, and vaccine strategies. J. Immunol. Res. 2016, 6803098 (2016).
  MedlineGoogle Scholar
• 42. Bos S, Gadea G, Despres P. Dengue: a growing threat requiring vaccine development for disease prevention. Pathogens Global Health 112(6), 294–305 (2018).
  MedlineGoogle Scholar
• 43. Thomas SJ. The necessity and quandaries of dengue vaccine development. Oxford University Press 203, 299–303 (2011).
  Google Scholar
• 44. Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34(14), 1643–1647 (2016).
  Medline CASGoogle Scholar
• 45. Wilder-Smith A, Smith P, Luo R et al. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report. Vaccine 37(36), 5137–5146 (2019).
  Medline CASGoogle Scholar
• 46. Wanyonyi MS. The Adjuvant Activity and Mechanisms of Action for Mastoparan 7 Peptide After Intranasal Immunization in Mice. Duke University (2014). https://dukespace.lib.duke.edu/dspace/handle/10161/9112
  Google Scholar
• 47. Hou J, Ye W, Chen J. Current development and challenges of tetravalent live-attenuated dengue vaccines. Front. Immunol. 13, 840104 (2022).
  Medline CASGoogle Scholar
• 48. Wan S-W, Lin C-F, Wang S et al. Current progress in dengue vaccines. J. Biomed. Sci. 20(1), 37 (2013).
  MedlineGoogle Scholar
• 49. Li W, Meng J, Ma X, Lin J, Lu X. Advanced materials for the delivery of vaccines for infectious diseases. Biosaf. Health 4(2), 95–104 (2022).
  CASGoogle Scholar
• 50. Yousefpour P, Ni K, Irvine DJ. Targeted modulation of immune cells and tissues using engineered biomaterials. Nat. Rev. Bioeng. 1(2), 107–124 (2023).
  Google Scholar
• 51. Pan J, Cui Z. Self-assembled nanoparticles: exciting platforms for vaccination. Biotechnol. J. 15(12), 2000087 (2020).
  CASGoogle Scholar
• 52. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev. Vaccines 15(4), 497–508 (2016).
  MedlineGoogle Scholar
• 53. Wilder-Smith A. Dengue vaccine development by the year 2020: challenges and prospects. Curr. Opin. Virol. 43, 71–78 (2020).
  Medline CASGoogle Scholar
• 54. McQuaid T. Sofosbuvir, a significant paradigm change in HCV treatment. J. Clin.Transl. Hepatol. 3(1), 27 (2015).
  MedlineGoogle Scholar
• 55. Capeding RZ, Luna IA, Bomasang E et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29(22), 3863–3872 (2011).
  MedlineGoogle Scholar
• 56. ClinicalTrials.gov. Study of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia (2020). https://clinicaltrials.gov/study/NCT01373281?tab=results
  Google Scholar
• 57. Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S. Dengue: status of current and under-development vaccines. Rev. Med. Virol. 30(4), e2101 (2020).
  MedlineGoogle Scholar
• 58. Hou J, Ye W, Chen J et al. Current development and challenges of tetravalent live-attenuated dengue vaccines. Front. Immunol. 13, 840104 (2022).
  Medline CASGoogle Scholar
• 59. Capeding MR, Tran NH, Hadinegoro SRS et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384(9951), 1358–1365 (2014).
  Medline CASGoogle Scholar
• 60. Osorio JE, Brewoo JN, Silengo SJ et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am. J. Trop. Med. Hyg. 84(6), 978 (2011).
  Medline CASGoogle Scholar
• 61. Biswal S, Reynales H, Saez-Llorens X et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med. 381(21), 2009–2019 (2019).
  Medline CASGoogle Scholar
• 62. Jin B-K, Odongo S, Radwanska M, Magez S. Nanobodies: a review of generation, diagnostics and therapeutics. Int. J. Mol. Sci. 24(6), 5994 (2023).
  Medline CASGoogle Scholar
• 63. Poggianella M, Bernedo R, Oloketuyi S, de Marco A. Nanobodies selectively binding to the idiotype of a dengue virus neutralizing antibody do not necessarily mimic the viral epitope. Biomolecules 13(3), 551 (2023).
  Medline CASGoogle Scholar
• 64. Watanabe Y. Mapping the glycan shields of enveloped viruses. University of Oxford (2020). https://ora.ox.ac.uk/objects/uuid:cf7049ae-488b-466c-b1be-eee7bac2cada
  Google Scholar
• 65. Calderón-Peláez M-A, Velandia-Romero ML, Bastidas-Legarda LY, Beltrán EO, Camacho-Ortega SJ, Castellanos JE. Dengue virus infection of blood–brain barrier cells: consequences of severe disease. Front. Microbiol. 10, 1435 (2019).
  MedlineGoogle Scholar
• 66. Biering SB, Harris E. A step towards therapeutics for dengue. Nature 598(7881), 420–421 (2021).
  Medline CASGoogle Scholar
• 67. Grab DJ, Sharma A, Burbulis I, Lehrer AT, Nerurkar V, Magez S. Nanobody LAMPoles: novel tools for dengue virus and Zika virus diagnosis. J. Immunol. 204(Suppl. 1), 82.24–82.24 (2020).
  Google Scholar
• 68. Mei Y, Chen Y, Sivaccumar JP, An Z, Xia N, Luo W. Research progress and applications of nanobody in human infectious diseases. Front. Pharmacol. 13, 963978 (2022).
  Medline CASGoogle Scholar
• 69. Singh L, Kruger HG, Maguire GE, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther. Adv. Infect. Dis. 4(4), 105–131 (2017).
  Medline CASGoogle Scholar
• 70. Duarte JL, Di Filippo LD, Araujo VHS et al. Nanotechnology as a tool for detection and treatment of arbovirus infections. Acta Trop. 216, 105848 (2021).
  Medline CASGoogle Scholar
• 71. Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10, 22 (2019).
  Medline CASGoogle Scholar
• 72. Khan HA, Ghufran M, Shams S et al. In-depth in vitro and in vivo anti-diabetic evaluations of Fagonia cretica mediated biosynthesized selenium nanoparticles. Biomed. Pharmacother. 164, 114872 (2023).
  Medline CASGoogle Scholar
• 73. Mohamed HEA, Khalil AT, Hkiri K et al. Structural, vibrational, optical and anticancer properties of Hyphaene thebaica reduced nano lanthanum oxide (La₂O₃). Appl. Organomet. Chem. 37(6), e7091 (2023).
  CASGoogle Scholar
• 74. Sher A, Khalil AT, Dogan N, Ayaz M, Ahmad K. Valorization and repurposing of Citrus limetta fruit waste for fabrication of multifunctional AgNPs and their diverse nanomedicinal applications. Appl. Biochem. Biotechnol. doi:10.1007/s12010-023-04646-z (2023) (Epub ahead of print).
  MedlineGoogle Scholar
• 75. Ankamwar B. Size and shape effect on biomedical applications of nanomaterials. Biomed. Engineer. Tech. App. Med. 93–114, http://dx.doi.org/10.5772/46121 (2012).
  Google Scholar
• 76. Maugi R, Hauer P, Bowen J, Ashman E, Hunsicker E, Platt M. A methodology for characterising nanoparticle size and shape using nanopores. Nanoscale 12(1), 262–270 (2020).
  Medline CASGoogle Scholar
• 77. Ghosh S, Ahmad R, Zeyaullah M, Khare SK. Microbial nano-factories: synthesis and biomedical applications. Front. Chem. 9, 626834 (2021).
  Medline CASGoogle Scholar
• 78. Khalil AT, Iqbal J, Abbasi BA et al. Current progress on the graphene-based nanocomposites for medical, environmental and energy applications. Nanoscience 133–151, 10.1039/9781839167218-00133 (2022).
  Google Scholar
• 79. Qasim Nasar M, Zohra T, Khalil AT et al. Seripheidium quettense mediated green synthesis of biogenic silver nanoparticles and their theranostic applications. Green Chem. Lett. Rev. 12(3), 310–322 (2019).
  Google Scholar
• 80. Rehman H, Ali W, Ali M et al. Delpinium uncinatum mediated green synthesis of AgNPs and its antioxidant, enzyme inhibitory, cytotoxic and antimicrobial potentials. PLOS ONE 18(4), e0280553 (2023).
  Medline CASGoogle Scholar
• 81. Moore TL, Cook AB, Bellotti E et al. Shape-specific microfabricated particles for biomedical applications: a review. Drug Deliv. Transl. Res. 12(8), 2019–2037 (2022).
  MedlineGoogle Scholar
• 82. Gomathi T, Rajeshwari K, Kanchana V, Sudha P, Parthasarathy K. Impact of nanoparticle shape, size, and properties of the sustainable nanocomposites. Sustainable Polymer Composites Nanocomposites 313–336, https://doi.org/10.1007/978-3-030-05399-4_11 (2019).
  Google Scholar
• 83. Cheng Z, Al Zaki A, Hui JZ et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903–910 (2012).
  Medline CASGoogle Scholar
• 84. Abd Ellah NH, Tawfeek HM, John J, Hetta HF. Nanomedicine as a future therapeutic approach for hepatitis C virus. Nanomedicine 14(11), 1471–1491 (2019).
  Google Scholar
• 85. Dash SR, Kundu CN. Advances in nanomedicine for the treatment of infectious diseases caused by viruses. Biomater. Sci. 11, 3431–3449 (2023).
  Medline CASGoogle Scholar
• 86. Wallis J, Shenton D, Carlisle RJC. Novel approaches for the design, delivery and administration of vaccine technologies. Clin. Exp. Immunol. 196(2), 189–204 (2019).
  Medline CASGoogle Scholar
• 87. Gao P, Xia G, Bao Z et al. Chitosan based nanoparticles as protein carriers for efficient oral antigen delivery. Int. J. Bio. Macromol. 91, 716–723 (2016).
  Medline CASGoogle Scholar
• 88. Fahimi H, Sadeghizadeh M, Hassan ZM, Auerswald H, Schreiber M. Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice. EXCLI J. 17, 1054 (2018).
  MedlineGoogle Scholar
• 89. Metz SW, Thomas A, Brackbill A et al. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype. PLOS Negl. Trop. Dis. 12(9), e0006793 (2018).
  MedlineGoogle Scholar
• 90. Versiani AF, Astigarraga RG, Rocha ES et al. Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice. J. Nanobiotechnol. 15, 1–13 (2017).
  MedlineGoogle Scholar
• 91. Osorio JE, Huang CY-H, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29(42), 7251–7260 (2011).
  Medline CASGoogle Scholar
• 92. Alen MM, Schols D. Dengue virus entry as target for antiviral therapy. J. Trop. Med. 2012, 628475 (2012).
  MedlineGoogle Scholar
• 93. Beckett CG, Kosasih H, Faisal I et al. Early detection of dengue infections using cluster sampling around index cases. Am. J. Trop. Med. Hyg. 72(6), 777–782 (2005).
  MedlineGoogle Scholar
• 94. Payne AF, Binduga-Gajewska I, Kauffman EB, Kramer LD. Quantitation of flaviviruses by fluorescent focus assay. J. Virol. Methods 134(1-2), 183–189 (2006).
  Medline CASGoogle Scholar
• 95. Fang Y, Tambo E, Xue J-B et al. Detection of DENV-2 and insect-specific flaviviruses in mosquitoes collected from Jeddah, Saudi Arabia. Front. Cell Infect. Microbiol. 11, 52 (2021).
  Google Scholar
• 96. Zhang B, Pinsky BA, Ananta JS et al. Diagnosis of Zika virus infection on a nanotechnology platform. Nat. Med. 23(5), 548–550 (2017).
  Medline CASGoogle Scholar
• 97. Carter JR, Balaraman V, Kucharski CA, Fraser TS, Fraser MJ. A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches. Virol. J. 10(1), 1–15 (2013).
  MedlineGoogle Scholar
• 98. Omar NAS, Fen YW, Abdullah J, Chik CENCE, Mahdi MA. Development of an optical sensor based on surface plasmon resonance phenomenon for diagnosis of dengue virus E-protein. Sens. Biosens. Res. 20, 16–21 (2018).
  Google Scholar
• 99. Hosseini S, Aeinehvand MM, Uddin SM et al. Microsphere integrated microfluidic disk: synergy of two techniques for rapid and ultrasensitive dengue detection. Sci. Rep. 5, 16485 (2015).
  Medline CASGoogle Scholar
• 100. Dhal A, Kalyani T, Ghorai S, Sahu NK, Jana SK. Recent development of electrochemical immunosensor for the diagnosis of dengue virus NSI protein: a review. Sens. Int. 1, 100030 (2020).
  Google Scholar
• 101. Balmaseda A, Saborio S, Tellez Y et al. Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. J. Clin. Virol. 43(3), 287–291 (2008).
  Medline CASGoogle Scholar
• 102. Antunes P, Watterson D, Parmvi M et al. Quantification of NS1 dengue biomarker in serum via optomagnetic nanocluster detection. Sci. Rep. 5, 16145 (2015).
  Medline CASGoogle Scholar
• 103. Yu HLL, Montesa CM, Rojas NRL, Enriquez EP. Nucleic-acid based lateral flow strip biosensor via competitive binding for possible dengue detection. J. Biosens. Bioelectron. 3(5), 128–134 (2012).
  Google Scholar
• 104. Ding X, Hu D, Chen Y et al. Full serotype-and group-specific NS1 capture enzyme-linked immunosorbent assay for rapid differential diagnosis of dengue virus infection. Clin. Vaccine Immunol. 18(3), 430–434 (2011).
  Medline CASGoogle Scholar
• 105. Oliveira N, Souza E, Ferreira D et al. A sensitive and selective label-free electrochemical DNA biosensor for the detection of specific dengue virus serotype 3 sequences. Sensors 15(7), 15562–15577 (2015).
  Medline CASGoogle Scholar
• 106. Castro LB, Kappl M, Petri DF. Adhesion forces between hybrid colloidal particles and concanavalin A. Langmuir 22(8), 3757–3762 (2006).
  Medline CASGoogle Scholar
• 107. Al-Dhabi NA, Arasu MV. Environmentally-friendly green approach for the production of zinc oxide nanoparticles and their anti-fungal, ovicidal, and larvicidal properties. Nanomaterials 8(7), 500 (2018).
  MedlineGoogle Scholar
• 108. Navakul K, Warakulwit C, Yenchitsomanus P-T et al. A novel method for dengue virus detection and antibody screening using a graphene-polymer based electrochemical biosensor. Biol. Med. 13(2), 549–557 (2017).
  CASGoogle Scholar
• 109. Agasti SS, Liong M, Peterson VM, Lee H, Weissleder R. Photocleavable DNA barcode-antibody conjugates allow sensitive and multiplexed protein analysis in single cells. J. Am. Chem. Soc. 134(45), 18499–18502 (2012).
  Medline CASGoogle Scholar
• 110. Nadiya Taha D. An electrochemical immunobiosensor for dengue virus NS1 protein detection/Nadiya Taha Darwish. University of Malaya (2016). http://studentsrepo.um.edu.my/6185/
  Google Scholar
• 111. Singhal C, Pundir C, Narang JJB. A genosensor for detection of consensus DNA sequence of dengue virus using ZnO/Pt-Pd nanocomposites. Biosens. Bioelectron. 97, 75–82 (2017).
  Medline CASGoogle Scholar
• 112. Nascimento HP, Oliveira MD, de Melo CP et al. An impedimetric biosensor for detection of dengue serotype at picomolar concentration based on gold nanoparticles–polyaniline hybrid composites. Colloids Surf. B Biointerfaces 86(2), 414–419 (2011).
  Medline CASGoogle Scholar
• 113. Jin S-A, Poudyal S, Marinero EE, Kuhn RJ, Stanciu LA. Impedimetric dengue biosensor based on functionalized graphene oxide wrapped silica particles. Electrochim. Acta 194, 422–430 (2016).
  CASGoogle Scholar
• 114. Suzuki K, Nakayama EE, Saito A et al. Evaluation of novel rapid detection kits for dengue virus NS1 antigen in Dhaka, Bangladesh, in 2017. Virol. J. 16(1), 1–15 (2019).
  Medline CASGoogle Scholar
• 115. Rai V, Hapuarachchi HC, Ng LC, Soh SH, Leo YS, Toh C-S. Ultrasensitive cDNA detection of dengue virus RNA using electrochemical nanoporous membrane-based biosensor. PLOS ONE 7(8), e42346 (2012).
  Medline CASGoogle Scholar
• 116. Ostromohov N, Schwartz O, Bercovici M. Focused upon hybridization: rapid and high sensitivity detection of DNA using isotachophoresis and peptide nucleic acid probes. Anal. Chem. 87(18), 9459–9466 (2015).
  Medline CASGoogle Scholar
• 117. Franco R, Pedrosa P, Carlos FF, Veigas B, Baptista PV. Gold nanoparticles for DNA/RNA-based diagnostics. Handbook Nanopart. 1339–1370, 10.1007/978-3-319-15338-4_31 (2015).
  Google Scholar
• 118. Ngo HT, Wang H-N, Fales AM, Nicholson BP, Woods CW, Vo-Dinh T. DNA bioassay-on-chip using SERS detection for dengue diagnosis. Analyst 139(22), 5655–5659 (2014).
  Medline CASGoogle Scholar
• 119. Yen C-W, de Puig H, Tam JO et al. Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses. Lab Chip 15(7), 1638–1641 (2015).
  Medline CASGoogle Scholar
• 120. Abdul Rahman S, Saadun R, Azmi NE et al. Label-free dengue detection utilizing PNA/DNA hybridization based on the aggregation process of unmodified gold nanoparticles. J. Nanomater. 2014, 839286 (2014).
  Google Scholar
• 121. Kabir MA, Zilouchian H, Younas MA, Asghar W. Dengue detection: advances in diagnostic tools from conventional technology to point of care. Biosensors 11(7), 206 (2021).
  Medline CASGoogle Scholar
• 122. Rozera R, Verma S, Kumar R, Haque A, Attri A. Herbal remedies, vaccines and drugs for dengue fever: emerging prevention and treatment strategies. Asian Pac. J. Trop. Med. 12(4), 147 (2019).
  CASGoogle Scholar
• 123. Gan CS, Lim SK, Chee CF, Yusof R, Heh CH. Sofosbuvir as treatment against dengue? Chem. Biol. Drug Des. 91(2), 448–455 (2018).
  Medline CASGoogle Scholar
• 124. Vinayagam S, Rajaiah P, Mukherjee A, Natarajan C. DNA-triangular silver nanoparticles nanoprobe for the detection of dengue virus distinguishing serotype. Spectrochim. Acta A Mol. Biomol. Spectrosc. 202, 346–351 (2018).
  Medline CASGoogle Scholar
• 125. Bonfá A, Saito RS, França RF, Fonseca BA, Petri FS. Poly(ethylene glycol) decorated poly(methylmethacrylate) nanoparticles for protein adsorption. Mat. Sci. Eng. C 31, 562–566 (2011).
  CASGoogle Scholar
• 126. Linting Z, Ruiyi L, Zaijun L, Qianfang X, Yinjun F, Junkang L. An immunosensor for ultrasensitive detection of aflatoxin B1 with an enhanced electrochemical performance based on graphene/conducting polymer/gold nanoparticles/the ionic liquid composite film on modified gold electrode with electrodeposition. Sensors Actuators B: Chem. 174, 359–365 (2012).
  Google Scholar
• 127. Wang Z, Ma L. Gold nanoparticle probes. Coordination Chem. Rev. 253, 1607–1618 (2009).
  CASGoogle Scholar
• 128. Zhang G-J, Chua JH, Chee R-E, Agarwal A, Wong SM. Label-free direct detection of MiRNAs with silicon nanowire biosensors. Biosensors Bioelectronics 24, 2504–2508 (2009).
  Medline CASGoogle Scholar
• 129. Chu P-T, Lin C-S, Chen W-J, Chen C-F, Wen H-W. Detection of gliadin in foods using a quartz crystal microbalance biosensor that incorporates gold nanoparticles. J. Agricultural Food Chem. 60, 6483–6492 (2012).
  Medline CASGoogle Scholar
• 130. Himuro T, Tsukamoto S, Saito Y. Electrical evaluation of DNA stretched and immobilized between triangular-shaped electrodes. J. Electronic Mat. 48, 1562–1567 (2019).
  CASGoogle Scholar
• 131. Briñas RP, Maetani M, Barchi JJ Jr. A survey of place-exchange reaction for the preparation of water-soluble gold nanoparticles. J. Colloid Interface Sci. 392, 415–421 (2013).
  Medline CASGoogle Scholar
• 132. Kumar DR, Kumar PS, Gandhi MR, Al-Dhabi NA, Paulraj MG, Ignacimuthu S. Delivery of chitosan/dsRNA nanoparticles for silencing of wing development vestigial (vg) gene in Aedes aegypti mosquitoes. Int. J. Bio. Macromol. 86, 89–95 (2016).
  Medline CASGoogle Scholar
• 133. Mansur JF, Alvarenga ES, Figueira-Mansur J et al. Effects of chitin synthase double-stranded RNA on molting and oogenesis in the chagas disease vector Rhodnius prolixus. Insect Biochem. Mol. Biol. 51, 110–121 (2014).
  Medline CASGoogle Scholar
• 134. Carvalho GC, Sábio RM, de Cássia Ribeiro T et al. Highlights in mesoporous silica nanoparticles as a multifunctional controlled drug delivery nanoplatform for infectious diseases treatment. Pharmaceut. Res. 37(10), 191 (2020).
  Medline CASGoogle Scholar
• 135. Mai WX, Meng H. Mesoporous silica nanoparticles: a multifunctional nano therapeutic system. Integr. Bio. 5(1), 19–28 (2013).
  Medline CASGoogle Scholar
• 136. Paul AM, Shi Y, Acharya D et al. Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J. Gen. Virol. 95(Pt 8), 1712 (2014).
  Medline CASGoogle Scholar
• 137. Gan VC. Dengue: moving from current standard of care to state-of-the-art treatment. Curr. Treatment Opt. Infectious Dis. 6, 208–226 (2014).
  MedlineGoogle Scholar
• 138. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 3(2), 133–149 (2008).
  MedlineGoogle Scholar
• 139. Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine 8(6), 969–981 (2013).
  CASGoogle Scholar